[Controversies accumulated around betablockers]

Vnitrni Lekarstvi
|June 16, 2015
PubMed

Insights

Betablockers remain vital in cardiology for hypertension and heart failure. However, recent analyses question their established role, prompting a review of current evidence and potential guideline changes.

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Medicine

Background:

  • Betablockers are a cornerstone in cardiovascular medicine, widely used for arterial hypertension, post-myocardial infarction secondary prevention, and heart failure with reduced ejection fraction.
  • Recent studies and analyses have introduced controversies, challenging the previously unquestioned efficacy and role of betablockers in specific cardiovascular conditions.

Purpose of the Study:

  • To review and summarize the accumulated controversies surrounding the use of betablockers in key cardiovascular indications.
  • To analyze the impact of these controversies on current clinical practice guidelines and predict future modifications.

Main Methods:

  • Systematic review of recent analyses and published information regarding betablocker use in cardiovascular medicine.
  • Focus on controversies in hypertension, secondary prevention of coronary artery disease, perioperative care, and heart failure treatment.

Main Results:

  • Significant controversies have emerged regarding the established indications for betablockers.
  • Some controversies have already influenced modifications in clinical practice guidelines.
  • Further guideline changes are anticipated in the near future based on ongoing research and debate.

Conclusions:

  • The role of betablockers in certain cardiovascular conditions is under re-evaluation.
  • Evidence-based controversies are driving changes in treatment guidelines for arterial hypertension, secondary prevention, perioperative care, and heart failure.
  • Clinicians and researchers must stay abreast of evolving recommendations for optimal patient care.

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.9K
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
2.0K
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
1.7K
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.4K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.2K
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
2.3K